Pipeline Society Title Data
Nelmastobart (STT-003) 2023 세계폐암학회(WCLC) Characterization of the Expression of BTN1A1 exclusive to PD-L1/PD-1 axis in Small Cell Lung Cancer using Spatial Biology Approach PDF
Nelmastobart (STT-003) ASCO 2023 A phase I study of Nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors PDF
Nelmastobart (STT-003) AACR 2023 Development of Diagnostic Antibodies For Anti-BTN1A1 Therapy, A Novel Immune Checkpoint Inhibitor Mutually Exclusive of PD-1/PD-L1 axis PDF
Nelmastobart (STT-003) AACR 2023 Pharmacokinetic Analyses and Immunophenotyping of Patients Treated With Nelmastobart (hSTC810), A Novel Immune Checkpoint Inhibitor PDF
Nelmastobart (STT-003) SITC 2022 A first-in human trial of hSTC810 (anti-BTN1A1 monoclonal antibody), targeting a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1 in patients with relapsed/refractory solid tumors. (Journal for ImmunoTherapy of Cancer 2022;10(2 PDF
Nelmastobart (STT-003) AACR 2022 Anti-BTN1A1 exhibits synergistic anti-tumor immunotherapeutic efficacy in combination with radiation therapy. (Cancer Res (2022) 82 (12_Supplement): 6321.) PDF
Nelmastobart (STT-003) AACR 2022 Humanized STC10 is a monoclonal antibody to BTN1A1, a novel immunotherapeutic target to be evaluated in a planned phase 1 study. (Cancer Res (2022) 82 (12_Supplement): 5318.) PDF
Nelmastobart (STT-003) SITC 2021 Targeting BTN1A1, an upstream regulator of PD-L1, as an alternative strategy in cancer immunotherapy PDF
Nelmastobart (STT-003) AACR-NCI-EORTC 2021 The Immune Checkpoint Protein BTN1A1 Suppresses T Cell Activation through Interactions with Gal9 and PD-1 (Mol Cancer Ther (2021) 20 (12_Supplement): LBA019.) PDF
Nelmastobart (STT-003) AACR 2021 BTN1A1: A Novel Immune Checkpoint for Cancer Immunotherapy Beyond The PD-1/PD-L1 Axis (Cancer Res (2021) 81 (13_Supplement): 1643.) PDF
PD-1 (STT-002) AACR 2020 Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity (Cancer Res. 2020 Jun 1;80(11):2298-2310.) PDF